The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Thirty Years of the Drug Candidate NAMI‐A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
Open accessAbstract
As anticipated in the title, this contribution is basically divided into two, strictly connected, parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 years after its synthesis and the discovery of its unprecedented antimetastatic properties in animal models at nontoxic dosages. The sections relating to the chemical and biological behavior of the complex, and the hypotheses on its mechanism(s) of action, are kept to a minimum, whereas more space is devoted to discussion of the results of the clinical investigations. The second part deals in detail with a number of undemonstrated misconceptions (or myths) that, over the years, have thrived around NAMI‐A and other ruthenium drug candidates, thus negatively affecting the whole field of Ru anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shannon, R. D. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001551 · Cited by 66,145
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Noble metals in medicine: Latest advances
Medici, S., Peana, M., Nurchi, V. M., Lachowicz, J. I., Crisponi, G., & Zoroddu, M. A. (2014) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.08.002 · Cited by 755
The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
Richardson, D. R., & Ponka, P. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/s0304-4157(96)00014-7 · Cited by 704
Metal complexes in cancer chemotherapy
Keppler, B. K. (1993) · Medical Entomology and Zoology · Cited by 688
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Trondl, R., Heffeter, P., Kowol, C. R., Jakupec, M. A., Berger, W., & Keppler, B. K. (2014) · Chem. Sci. · doi:10.1039/c3sc53243g · Cited by 675
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Recent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
The Discovery and Development of Cisplatin
Alderden, R. A., Hall, M. D., & Hambley, T. W. (2006) · Journal of Chemical Education · doi:10.1021/ed083p728 · Cited by 532
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Knox, R. J., Friedlos, F., Lydall, D. A., & Roberts, J. J. (1986) · PubMed · Cited by 498
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Self-citationNoguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., & Maeda, H. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00563.x · Cited by 470
The intracellular trafficking pathway of transferrin
Mayle, K. M., Le, A. M., & Kamei, D. T. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.09.009 · Cited by 466
Habtemariam, A., Melchart, M., Fernández, R., Parsons, S., Oswald, I. D. H., Parkin, A., Fabbiani, F. P. A., Davidson, J. E., Dawson, A., Aird, R. E., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060596m · Cited by 456
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Transferrin as a Metal Ion Mediator
Sun, H., Li, H., & Sadler, P. J. (1999) · Chemical Reviews · doi:10.1021/cr980430w · Cited by 377
Leijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0179-1 · Cited by 374
Self-citationCisplatin Binding Sites on Human Albumin
Ivanov, A. I., Christodoulou, J., Parkinson, J. A., Barnham, K. J., Tucker, A., Woodrow, J., & Sadler, P. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14721 · Cited by 362
A categorization of metal anticancer compounds based on their mode of action
Gianferrara, T., Bratsos, I., & Alessio, E. (2009) · Dalton Transactions · doi:10.1039/b905798f · Cited by 336
Self-citationReedijk, B. J. (2008) · Platinum Metals Review · doi:10.1595/147106708x255987 · Cited by 312
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Catalytic organometallic anticancer complexes
Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800076105 · Cited by 303
Adhireksan, Z., Davey, G. E., Campomanes, P., Groessl, M., Clavel, C. M., Yu, H., Nazarov, A. A., Yeo, C. H. F., Ang, W. H., Dröge, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4462 · Cited by 297
Pierroz, V., Joshi, T., Leonidova, A., Mari, C., Schur, J., Ott, I., Spiccia, L., Ferrari, S., & Gasser, G. (2012) · Journal of the American Chemical Society · doi:10.1021/ja307288s · Cited by 296
Ruthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
Molecular control of vertebrate iron homeostasis by iron regulatory proteins
Wallander, M. L., Leibold, E. A., & Eisenstein, R. S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.004 · Cited by 287
Wang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., & Sadler, P. J. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200304724 · Cited by 254
Metal-based antitumour drugs in the post-genomic era: what comes next?
Sava, G., Bergamo, A., & Dyson, P. J. (2011) · Dalton Transactions · doi:10.1039/c1dt10522a · Cited by 231
Smalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 230
Ruthenium Anticancer Compounds: Challenges and Expectations
Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E. (2007) · CHIMIA · doi:10.2533/chimia.2007.692 · Cited by 225
Self-citationLinking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 219
Pongratz, M., Schluga, P., Jakupec, M. A., Arion, V. B., Hartinger, C. G., Allmaier, G., & Keppler, B. K. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b309160k · Cited by 206
The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
Kratz, F., Hartmann, M., Keppler, B., & Messori, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41984-3 · Cited by 204
The Design of Organometallic Ruthenium Arene Anticancer Agents
Dougan, S. J., & Sadler, P. J. (2007) · CHIMIA · doi:10.2533/chimia.2007.704 · Cited by 202
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
Sava, G., Capozzi, I., Clerici, K., Gagliardi, G., Alessio, E., & Mestroni, G. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006521715400 · Cited by 183
Self-citationSchäfer, S., Ott, I., Gust, R., & Sheldrick, W. S. (2007) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200700206 · Cited by 175
Reisner, E., Arion, V. B., Guedes da Silva, M. F. C., Lichtenecker, R., Eichinger, A., Keppler, B. K., Kukushkin, V. Y., & Pombeiro, A. J. L. (2004) · Inorganic Chemistry · doi:10.1021/ic049479c · Cited by 173
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Heffeter, P., Böck, K., Atil, B., Reza Hoda, M. A., Körner, W., Bartel, C., Jungwirth, U., Keppler, B. K., Micksche, M., Berger, W., et al. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0642-1 · Cited by 173
Bergamo, A., Gagliardi, R., Scarcia, V., Furlani, A., Alessio, E., Mestroni, G., & Sava, G. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38169-8 · Cited by 160
Self-citationDömötör, O., Hartinger, C. G., Bytzek, A. K., Kiss, T., Keppler, B. K., & Enyedy, É. A. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0944-6 · Cited by 145
Luigi Messori, A., Orioli, P., Vullo, D., Alessio, E., & Iengo, E. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01121.x · Cited by 143
Self-citationNew Ruthenium Complexes for the Treatment of Cancer
Keppler, B. K., Henn, M., Juhl, U. M., Berger, M. R., Niebl, R., & Wagner, F. E. (1989) · Progress in clinical biochemistry and medicine · doi:10.1007/978-3-642-74760-1_3 · Cited by 143
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138
Antagonizing STAT3 Dimerization with a Rhodium(III) Complex
Ma, D., Liu, L., Leung, K., Chen, Y., Zhong, H., Chan, D. S., Wang, H., & Leung, C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201404686 · Cited by 128
Bijelic, A., Theiner, S., Keppler, B. K., & Rompel, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00600 · Cited by 128
Liu, M., Lim, Z. J., Gwee, Y. Y., Levina, A., & Lay, P. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200906079 · Cited by 122
Zorzet, S., Bergamo, A., Cocchietto, M., Sorc, A., Gava, B., Alessio, E., Iengo, E., & Sava, G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38990-6 · Cited by 120
Self-citationRuthenium-based compounds and tumour growth control (review).
Sava, G., & Bergamo, A. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.2.353 · Cited by 118
Bytzek, A. K., Koellensperger, G., Keppler, B. K., & Hartinger, C. G. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.02.037 · Cited by 114
Antagonizing STAT3 Dimerization with a Rhodium(III) Complex
Ma, D., Liu, L., Leung, K., Chen, Y., Zhong, H., Chan, D. S., Wang, H., & Leung, C. (2014) · Angewandte Chemie · doi:10.1002/ange.201404686 · Cited by 109
Tan, C., Wu, S., Lai, S., Wang, M., Chen, Y. X., Zhou, L., Zhu, Y., Lian, W., Peng, W., Ji, L., et al. (2011) · Dalton Transactions · doi:10.1039/c1dt10084j · Cited by 105
Gava, B., Zorzet, S., Spessotto, P., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095141 · Cited by 94
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
Morbidelli, L., Donnini, S., Filippi, S., Luigi Messori, A., Piccioli, F., Orioli, P., Sava, G., & Ziche, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600906 · Cited by 92
Sava, G., Frausin, F., Cocchietto, M., Vita, F., Podda, E., Spessotto, P., Furlani, A., Scarcia, V., & Zabucchi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.034 · Cited by 91
Synthesis of Cycloruthenated Compounds as Potential Anticancer Agents
Leyva, L., Sirlin, C., Rubio, L., Franco, C., Lagadec, R. L., Spencer, J., Bischoff, P. L., Gaiddon, C., Loeffler, J., & Pfeffer, M. (2007) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200601149 · Cited by 85
Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR
Cetinbas, N. M., Webb, M. I., Dubland, J. A., & Walsby, C. J. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0578-5 · Cited by 85
Preparation and metabolism of a cisplatin/serum protein complex
Cole, W. C., & Wolf, W. (1980) · Chemico-Biological Interactions · doi:10.1016/0009-2797(80)90128-3 · Cited by 85
Timerbaev, A. R., Rudnev, A. V., Semenova, O. P., Hartinger, C. G., & Keppler, B. K. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.03.020 · Cited by 84
Piccioli, F., Sabatini, S., Luigi Messori, A., Orioli, P., Hartinger, C. G., & Keppler, B. K. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.002 · Cited by 83
Will, J., Wolters, D. A., & Sheldrick, W. S. (2008) · ChemMedChem · doi:10.1002/cmdc.200800151 · Cited by 82
Vergara, A., D’Errico, G., Montesarchio, D., Mangiapia, G., Paduano, L., & Merlino, A. (2013) · Inorganic Chemistry · doi:10.1021/ic4004142 · Cited by 70
Chitambar, C. R., Wereley, J. P., & Matsuyama, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0285 · Cited by 60
Keppler, B. K., Wehe, D., Endres, H., et al. (1987) · Inorganic Chemistry · doi:10.1021/ic00253a014 · Cited by 59
Ruthenium and Other Non‐Platinum Anticancer Compounds
Bratsos, I., Gianferrara, T., Alessio, E., Hartinger, C. G., Jakupec, M. A., & Keppler, B. K. (2011) · Wiley eBooks · doi:10.1002/9783527633104.ch5 · Cited by 54
Self-citationPerez, R. P., O'Dwyer, P. J., Handel, L. M., Ozols, R. F., & Hamilton, T. C. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480219 · Cited by 49
EPR as a probe of the intracellular speciation of ruthenium(iii) anticancer compounds
Webb, M. I., & Walsby, C. J. (2013) · Metallomics · doi:10.1039/c3mt00090g · Cited by 48
Timerbaev, A. R., Foteeva, L. S., Rudnev, A. V., Abramski, J. K., Pawlak, K., Hartinger, C. G., Jarosz, M., & Keppler, B. K. (2007) · Electrophoresis · doi:10.1002/elps.200600707 · Cited by 47
Brindell, M., Piotrowska, D., Shoukry, A. A., Stochel, G., & van Eldik, R. (2007) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-007-0234-x · Cited by 42
Webb, M. I., & Walsby, C. J. (2015) · Dalton Transactions · doi:10.1039/c5dt02021b · Cited by 41
Jassem, J., Krzakowski, M. J., Roszkowski, K., Ramlau, R., Słomiński, J. M., Szczęsna, A., Krawczyk, K., Możejko-Pastewka, B., Lis, J., & Miracki, K. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00286-0 · Cited by 37
Davies, N. P., Rahmanto, Y. S., Chitambar, C. R., & Richardson, D. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099044 · Cited by 37
Fanning, J. D., Biddle, W. C., Goldrosen, M. H., et al. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90416-i · Cited by 32
Ga3+ as a mechanistic probe in Fe3+ transport: characterization of Ga3+ interaction with FbpA
Weaver, K. D., Heymann, J. J., Mehta, A., Roulhac, P. L., Anderson, D. S., Nowalk, A. J., Adhikari, P., Mietzner, T. A., Fitzgerald, M. C., & Crumbliss, A. L. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0376-5 · Cited by 27
Pacor, S., Sava, G., Ceschia, V., et al. (1991) · Chemico-Biological Interactions · doi:10.1016/0009-2797(91)90016-z · Cited by 23
Hostetter, A. A., Miranda, M. L., DeRose, V. J., & Holman, K. L. M. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0806-7 · Cited by 22
Casarsa, C., Mischis, M. T., & Sava, G. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.017 · Cited by 21
Cited by
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Alessio, E., & Messori, L. (2019) · Molecules · doi:10.3390/molecules24101995 · Cited by 385
Self-citationMetal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Metadata
- Authors
- Alessio, E.
- Venue
- European Journal of Inorganic Chemistry
- Publisher
- Wiley
- Published
- 2016-09-28
- Volume
- 2017
- Issue
- 12
- Pages
- 1549-1560
- ISSN
- 1099-0682 (ISSN-L)
- 1434-1948
- OpenAlex
- W2526296695
- Cited by
- 388
- References
- 92
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.